These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2255588)

  • 41. [End filtration in infusion therapy].
    Zimmermann K
    Krankenpfl Soins Infirm; 2015; 108(11):34-5. PubMed ID: 26677656
    [No Abstract]   [Full Text] [Related]  

  • 42. [Study on particle contamination produced by syringe needles and rubber stoppers for pharmaceutical solutions].
    Zhao L; Wang HS; Han ZF
    Zhonghua Hu Li Za Zhi; 1997 Jan; 32(1):12-4. PubMed ID: 9304949
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-destructive optical screening method for particulate matter in intravenous solutions.
    Passl WJ; Rumsey N; Trotter A
    Analyst; 1980 May; 105(1250):512-5. PubMed ID: 7396221
    [No Abstract]   [Full Text] [Related]  

  • 44. Evaluation of acceptance criteria for particulate limits for small-volume parenteral products.
    Tsuji K; Lewis AR
    J Pharm Sci; 1978 Jan; 67(1):50-5. PubMed ID: 619115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dynamic Image Analysis To Evaluate Subvisible Particles During Continuous Drug Infusion In a Neonatal Intensive Care Unit.
    Perez M; Décaudin B; Maiguy-Foinard A; Barthélémy C; Lebuffe G; Storme L; Odou P
    Sci Rep; 2017 Aug; 7(1):9404. PubMed ID: 28839243
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utilization of the tyndall effect for enhanced visual detection of particles in compatibility testing of intravenous fluids: validity and reliability.
    Staven V; Waaseth M; Wang S; Grønlie I; Tho I
    PDA J Pharm Sci Technol; 2015; 69(2):270-83. PubMed ID: 25868993
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Quantitative analysis of particulate matter in infusion solutions, administration sets and additives (author's transl)].
    Ahnefeld FW; Klaus E
    Anaesthesist; 1977 Aug; 26(8):476-84. PubMed ID: 907081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the Royco 367 small volume sample feeder for estimation of particulate contamination in ampoules [proceedings].
    Davies PJ; Smart JD
    J Pharm Pharmacol; 1979 Dec; 31 Suppl():108P. PubMed ID: 42681
    [No Abstract]   [Full Text] [Related]  

  • 49. Intravenous administration sets. The effect of flushing and filtration on particulate contamination.
    Harrison MJ; Healy TE
    Br J Anaesth; 1974 Jan; 46(1):59-65. PubMed ID: 4820936
    [No Abstract]   [Full Text] [Related]  

  • 50. [Use of microfilters within the scope of infusion therapy].
    Böttiger BW; Bach A
    Infusionsther Transfusionsmed; 1994 Feb; 21(1):42-51. PubMed ID: 8173311
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of Particulate Matter in Liquid-Finished Dosage Forms.
    Duchek J; Havasi B
    PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cut-off fragments of rubber caps of bottles of contrast material: foreign bodies in the drip infusion system.
    Sakai O; Furuse M; Nakashima N
    AJNR Am J Neuroradiol; 1996; 17(6):1194-5. PubMed ID: 8791939
    [No Abstract]   [Full Text] [Related]  

  • 53. Particulate contamination in parenterals: current issues.
    Groves MJ
    Boll Chim Farm; 1991 Oct; 130(9):347-54. PubMed ID: 1799429
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Microfilters within the scope of infusion therapy--possibilities and problems in retention of microbial and particle contaminants].
    Bach A; Böttiger BW
    Zentralbl Chir; 1994; 119(4):268-75. PubMed ID: 8203178
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Parameter for assessing parenteral cleanliness based on particle-size distributions.
    Blanchard J; Schwartz JA; Byrne DM
    J Pharm Sci; 1977 Aug; 66(8):1083-6. PubMed ID: 894493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The potential hazard of particulate contamination of cardioplegic solutions.
    Robinson LA; Braimbridge MV; Hearse DJ
    J Thorac Cardiovasc Surg; 1984 Jan; 87(1):48-58. PubMed ID: 6690859
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Particulate contamination of lyophilized amphotericin B preparation during reconstitution process.
    Sendo T; Hirakawa M; Makino K; Nakashima K; Kataoka Y; Oishi R
    J Clin Pharm Ther; 2001 Apr; 26(2):87-91. PubMed ID: 11350530
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative estimation of particulate matter in pharmaceutical preparations intended for intravenous administration.
    Bikhazi AB; Shiatis JA; Haddad AF
    J Pharm Sci; 1977 Feb; 66(2):181-6. PubMed ID: 839413
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between length of time and contamination in open intravenous solutions.
    Amonsen S; Gren JE
    Nurs Res; 1978; 27(6):372-4. PubMed ID: 251249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Contamination of intravenous infusion systems--the effect of changing administration sets.
    Jakobsen CJ; Grabe N; Nielsen E; Højbjerg T; Damm M; Lorentzen K; Ersgaard HV; Villadsen J; Heebøl-Holm B; Madsen JI
    J Hosp Infect; 1986 Nov; 8(3):217-23. PubMed ID: 2878025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.